Your browser doesn't support javascript.
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.
Suryawanshi, Rahul K; Chen, Irene P; Ma, Tongcui; Syed, Abdullah M; Brazer, Noah; Saldhi, Prachi; Simoneau, Camille R; Ciling, Alison; Khalid, Mir M; Sreekumar, Bharath; Chen, Pei-Yi; Kumar, G Renuka; Montano, Mauricio; Gascon, Ronne; Tsou, Chia-Lin; Garcia-Knight, Miguel A; Sotomayor-Gonzalez, Alicia; Servellita, Venice; Gliwa, Amelia; Nguyen, Jenny; Silva, Ines; Milbes, Bilal; Kojima, Noah; Hess, Victoria; Shacreaw, Maria; Lopez, Lauren; Brobeck, Matthew; Turner, Fred; Soveg, Frank W; George, Ashley F; Fang, Xiaohui; Maishan, Mazharul; Matthay, Michael; Morris, Mary Kate; Wadford, Debra; Hanson, Carl; Greene, Warner C; Andino, Raul; Spraggon, Lee; Roan, Nadia R; Chiu, Charles Y; Doudna, Jennifer A; Ott, Melanie.
  • Suryawanshi RK; Gladstone Institutes, San Francisco, CA, USA.
  • Chen IP; Gladstone Institutes, San Francisco, CA, USA.
  • Ma T; Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, USA.
  • Syed AM; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Brazer N; Quantitative Biosciences Institute COVID-19 Research Group, University of California, San Francisco, San Francisco, CA, USA.
  • Saldhi P; Gladstone Institutes, San Francisco, CA, USA.
  • Simoneau CR; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Ciling A; Gladstone Institutes, San Francisco, CA, USA.
  • Khalid MM; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.
  • Sreekumar B; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Chen PY; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Kumar GR; Gladstone Institutes, San Francisco, CA, USA.
  • Montano M; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Gascon R; Quantitative Biosciences Institute COVID-19 Research Group, University of California, San Francisco, San Francisco, CA, USA.
  • Tsou CL; Gladstone Institutes, San Francisco, CA, USA.
  • Garcia-Knight MA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.
  • Sotomayor-Gonzalez A; Gladstone Institutes, San Francisco, CA, USA.
  • Servellita V; Gladstone Institutes, San Francisco, CA, USA.
  • Gliwa A; Gladstone Institutes, San Francisco, CA, USA.
  • Nguyen J; Gladstone Institutes, San Francisco, CA, USA.
  • Silva I; Gladstone Institutes, San Francisco, CA, USA.
  • Milbes B; Michael Hulton Center for HIV Cure Research at Gladstone, San Francisco, CA, USA.
  • Kojima N; Gladstone Institutes, San Francisco, CA, USA.
  • Hess V; Gladstone Institutes, San Francisco, CA, USA.
  • Shacreaw M; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.
  • Lopez L; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Brobeck M; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Turner F; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Soveg FW; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • George AF; Curative Inc., San Dimas, CA, USA.
  • Fang X; Curative Inc., San Dimas, CA, USA.
  • Maishan M; Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
  • Matthay M; Curative Inc., San Dimas, CA, USA.
  • Morris MK; Curative Inc., San Dimas, CA, USA.
  • Wadford D; Curative Inc., San Dimas, CA, USA.
  • Hanson C; Curative Inc., San Dimas, CA, USA.
  • Greene WC; Curative Inc., San Dimas, CA, USA.
  • Andino R; Gladstone Institutes, San Francisco, CA, USA.
  • Spraggon L; Gladstone Institutes, San Francisco, CA, USA.
  • Roan NR; Department of Urology, University of California, San Francisco, San Francisco, CA, USA.
  • Chiu CY; Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA.
  • Doudna JA; Department of Anesthesia, Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA.
  • Ott M; Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA.
Nature ; 607(7918): 351-355, 2022 07.
Article in English | MEDLINE | ID: covidwho-1852428
ABSTRACT
SARS-CoV-2 Delta and Omicron are globally relevant variants of concern. Although individuals infected with Delta are at risk of developing severe lung disease, infection with Omicron often causes milder symptoms, especially in vaccinated individuals1,2. The question arises of whether widespread Omicron infections could lead to future cross-variant protection, accelerating the end of the pandemic. Here we show that without vaccination, infection with Omicron induces a limited humoral immune response in mice and humans. Sera from mice overexpressing the human ACE2 receptor and infected with Omicron neutralize only Omicron, but not other variants of concern, whereas broader cross-variant neutralization was observed after WA1 and Delta infections. Unlike WA1 and Delta, Omicron replicates to low levels in the lungs and brains of infected animals, leading to mild disease with reduced expression of pro-inflammatory cytokines and diminished activation of lung-resident T cells. Sera from individuals who were unvaccinated and infected with Omicron show the same limited neutralization of only Omicron itself. By contrast, Omicron breakthrough infections induce overall higher neutralization titres against all variants of concern. Our results demonstrate that Omicron infection enhances pre-existing immunity elicited by vaccines but, on its own, may not confer broad protection against non-Omicron variants in unvaccinated individuals.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccination / Cross Protection / SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Nature Year: 2022 Document Type: Article Affiliation country: S41586-022-04865-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccination / Cross Protection / SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Nature Year: 2022 Document Type: Article Affiliation country: S41586-022-04865-0